



Federal Retail Pharmacy Program Updates

Federal Retail Pharmacy Partnership for COVID-19 website

Find up to date information and newsletters on our [website](#) for the Federal Retail Pharmacy Partnership for COVID-19.

[Sitio web en Español](#) para participantes del programa de vacunas COVID

Vaccine program updates

Bivalent booster update

Important notes:

The monovalent vaccines are **NO LONGER** authorized for boosters. If you have appointments for boosters, please reschedule for when your locations have the bivalent vaccines available.

Please note that any monovalent booster dose that was administered after the bivalent booster was authorized by the FDA needs to be reported to VAERS. Please see the **Clinical Considerations** information below for more details.

ORDERING: Bivalent vaccines are currently available for preorder through the ABC Order COVID portal, but please note that the Moderna supply is initially limited. ***Please note that if you order (or have already ordered) the Moderna bivalent booster, those orders will be fulfilled on a first in-first out basis as additional product is available to ship. You may not receive the product for up to three weeks. Please see below recommendation to order Pfizer bivalent boosters for quicker access.***

Bivalent booster CDC updates

- If pharmacies have administered a monovalent booster since approval of bivalent: they can submit a bulk VAERS report with number of vaccines administered since 8/31.
- Messaging around boosters and spacing times
- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-d>
- Actions to take after an error has occurred and what actions to take moving forward:

Bivalent vaccine incorrectly administered for the primary series	<ul style="list-style-type: none"> • Bivalent Pfizer-BioNTech vaccine: Do not repeat dose. • Bivalent Moderna vaccine: Repeat dose immediately (no minimum interval) because administration of the booster dose will result in a lower-than-authorized dose.
Monovalent vaccine incorrectly administered for a booster dose (if bivalent booster indicated)	<ul style="list-style-type: none"> • In general, do not repeat dose. • However, providers may administer 1 bivalent booster dose as a repeat dose based on clinical judgement and patient preference. In this case, space the repeat dose after the dose given in error by at least 2 months.

- Pharmacies are able to opt out of ancillary kits for bivalents orders.
- Vaccinefinder has been updated for flu/bivalent boosters. Pharmacies are encouraged to use and consistently update VaccineFinder so patients can locate their pharmacies when looking for vaccines.

CDC recommends everyone 12+ get updated COVID-19 booster, when eligible

The Centers for Disease Control and Prevention (CDC) endorsed the Advisory Committee on Immunization Practices (ACIP)'s recommendation that people ages 12 and older receive an updated COVID-19 booster for broader protection before a possible surge in COVID-19 illnesses later this fall and winter.

CDC's recommendation applies to over 200 million people in the United States and follows FDA emergency use authorization of the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters on August 31, 2022.

Updated COVID-19 boosters can both help restore protection that has waned since previous vaccination and provide broader protection against newer variants. They target the most recent Omicron subvariants, BA.4 and BA.5, that are more transmissible and

more likely to be able to evade antibodies made against earlier subvariants. The Food and Drug Administration (FDA) advised manufacturers earlier this year to add these subvariant components to their COVID-19 vaccine boosters.

- The Pfizer-BioNTech updated COVID-19 booster is recommended for adolescents and adults ages 12 years and older, and the Moderna updated COVID-19 booster for adults ages 18 years and older.
- Everyone who is eligible—including those who are moderately or severely immunocompromised—are recommended to receive 1 dose of the updated vaccine.
- People are eligible to receive updated boosters at least 2 months since their last COVID-19 dose (either the final primary series dose or the last booster).
- ACIP also discussed updated COVID-19 boosters for younger age groups—including Pfizer-BioNTech for children ages 5 through 11 years, and Moderna for children and adolescents ages 6 through 17 years. When FDA authorizes these vaccines and age groups, CDC will expand its recommendations accordingly.

CDC and ACIP recommend giving flu vaccines and COVID-19 vaccines [at the same time](#), based on studies conducted throughout the COVID-19 pandemic.

CDC has also streamlined what it means to be “up to date” with COVID-19 vaccines.

- CDC has long recommended that everyone [stays up to date](#) with COVID-19 vaccination, including receiving all primary series and booster doses.
- You are up to date if you have completed a primary series and received the most recent booster dose recommended for you by CDC.
- COVID-19 vaccines are safe and effective, and CDC recommends everyone stay up to date.
- The COVID-19 vaccines authorized for use in the U.S. continue to reduce the risk of severe disease, hospitalization, and death, including against the Omicron variant and subvariants.
- COVID-19 vaccines have undergone and continue to undergo the most intense safety monitoring in U.S. history. Clinical research has demonstrated the safety and effectiveness of the recommended COVID-19 primary series vaccines, as well as the recommended COVID-19 boosters.
- CDC recommends everyone [stays up to date](#) with COVID-19 vaccination. This means everyone:
 - Ages 6 months through 4 years should get all COVID-19 primary series doses.
 - Ages 5 years and older should get all COVID-19 primary series doses, plus the most recent booster dose recommended for them.
 - You can check if and when to get COVID-19 boosters with CDC’s COVID-19 booster tool.
 - V-safe is a safety monitoring system that lets you share with CDC how you, or your dependent, feel after getting a COVID-19 vaccine. People can enroll in v-safe after any dose of a COVID-19 vaccine by going to vsafe.cdc.gov.
- [Interim Clinical Considerations](#)
- [Appendices](#)

- [At-a-glance schedule](#)
- [Managing Anaphylaxis webpage](#)
- [New Archived Schedule webpage](#)
- [iCC FAQs](#)
- [EUIs](#)
 - [Moderna HCP FS](#)
 - [Moderna Recipient FS](#)
 - [Pfizer HCP FS](#)
 - [Pfizer Recipient FS](#)
 - [EUI FAQs](#)
 - Spanish Fact Sheets are not yet available
- [Pfizer age transition pdf](#) (goodbye, purple cap)

Code set reminders

Drug Compendia have published Bivalent Booster Codes by August 31, 2022.

- **Please check and verify that you are seeing Bivalent Booster Code sets for both Pfizer and Moderna in systems to ensure system readiness.** Payer systems will also be impacted by those codes.

AMA published CPT Codes for Bivalent Boosters:

- <https://www.ama-assn.org/press-center/press-releases/ama-announces-cpt-update-covid-19-boosters-adapted-omicron>
- <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>

AMA Announces CPT update for COVID-19 boosters adapted to omicron

- The AMA announced an editorial update to (CPT)[®] that includes eight new codes for the bivalent COVID-19 vaccine booster doses from Moderna and Pfizer-BioNTech.

Novavax update

Novavax should still be ordered by emailing the request with your NCPDP number to the COVID email box at COVIDVaccines@AmerisourceBergen.com.

- [Updated Clinical Considerations](#)

Oral therapeutics program updates

The Administration for Strategic Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) announced the authorization of an extension to the shelf life from 12 months to 18 months for certain lots of the Pfizer antiviral therapy, Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use), which is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients (12 years of age and older weighing at least 40kg).

As a result of this extension, lots of Paxlovid with dates of expiry from July 2022 to May 2023 may be stored for an additional six months from the labeled date of expiry (see Table 1 below). As required by the emergency use authorization, unopened cartons of Paxlovid (300 mg nirmatrelvir and 100 mg ritonavir, or 150 mg nirmatrelvir and 100 mg ritonavir), must be appropriately held in accordance with storage conditions detailed in the authorized [Fact Sheet for Health Care Providers](#). FDA granted this extension following a thorough review of data submitted by Pfizer.

Table 1: Extended Expiry Dating for Paxlovid Authorized under EUA 105

Labeled Expiry Date (YYYY-MM)	Extended Expiry Date (YYYY-MM)
2022-07	2023-01
2022-08	2023-02
2022-11	2023-05
2022-12	2023-06
2023-01	2023-07
2023-02	2023-08
2023-03	2023-09
2023-04	2023-10
2023-05	2023-11

Please contact COVID19Therapeutics@hhs.gov with any questions and visit the [ASPR website](#) for additional information regarding Paxlovid.

Please note that any monovalent booster dose that was administered after the bivalent booster was authorized by the FDA needs to be reported to VAERS.

Resources

Updated Implementation and Allocation Guides

- [Therapeutics Allocation guide](#)
- [Therapeutics implementation guide](#)
- [Vaccine implementation guide](#)
- [Vaccine allocation guide](#)

COVID-19 Treatment Marketing Materials

Let your patients know that you have the latest booster shot available at your pharmacy with new print and digital marketing materials. Visit the “COVID-19 Vaccine” library in [Brand Central Station](#) and [SOCi](#) to access the materials.



Surveys, reporting, reminders

Are you interested in dispensing COVID-19 antiviral therapies?

If you are currently enrolled in the vaccine program and are interested in participating in the antiviral program, please email the Elevate Enrollments team at elevateenrollments@amerisourcebergen.com.

At this time, only pharmacies enrolled in the vaccine program may participate in the antiviral program.

Questions? Continue to work with your Business Coach or Sales Executive or send questions to COVIDVaccines@AmerisourceBergen.com. Please include your pharmacy

name and NCPDP on all communications. This information will help us expedite our response to you.

AmerisourceBergen



[click](#)